Refine by
Drug Development Program Articles & Analysis
32 news found
“This achievement demonstrates our commitment to providing our customers with the highest quality materials for their drug development programs. We are confident that this registration will help to streamline and accelerate the development of new ...
PROTACs represent a revolutionary paradigm in drug discovery, harnessing the cell's own protein degradation machinery to selectively eliminate targeted proteins. ...
This improved outlook comes amid the company’s potential blockbuster drugs tracking ahead of schedule and targeted investments in Research and Development (R&D) replenishing its pharmaceutical development pipeline. ...
ByBayer AG
(“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. ...
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in ...
Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. MVP is MDA’s drug development program, which is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular disorders. MVP ...
BynVector
(CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). ...
Fluidda, leader in the field of Functional Respiratory Imaging and developer of the medical device Broncholab®, today announced an exclusive collaboration with Nanopharm, an Aptar Pharma company and a leader in contract research and development services for orally inhaled and nasal drug products (OINDPs). ...
ByFluidda
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...
About VeriSIM Life VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM is a first-in-class 'virtual drug ...
The company recently announced the launch of ligand-based pharmacophore model service for scientists to accelerate the drug candidate development process. Molecular docking technology remains the most popular structure-based drug design method that takes full advantage of protein-ligand interaction information. ...
(Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and ...
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. The company has recently announced Protein Drug Modification Analysis service to help researchers determine the modification type, modification site, and modification structure of protein drugs. Mature protein medicines have complete ...
Our program includes a core curriculum covering key aspects of drug development, experiential learning, structured collaboration with biotech professionals, and engagement with many other early-stage biotech companies. ...
("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...
Morriss has a track record of developing successful drug programs and building clinical teams for all phases of development. ...
The area of drug development is a veritable minefield with many junctures where a project can come to an abrupt end. ...
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. ...
ByDiamiR
The company recently unveiled its growing portfolio of emerging joint venture companies, with drug development programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. ...
As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer, Stevanato Group. Moberg brings 30+ years of expertise to Bexson, ...